Are vancomycin trough concentrations adequate for optimal dosing? - Wikidata - wikimedia - TriplyDB

Are vancomycin trough concentrations adequate for optimal dosing?

Are vancomycin trough concentrations adequate for optimal dosing?

http://www.wikidata.org/entity/Q37544400

about

Review of vancomycin-induced renal toxicity: an update Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis Optimizing the Clinical Use of Vancomycin Comparison of open-access vancomycin dosing websites.The Whole Price of Vancomycin: Toxicities, Troughs, and Time Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant Staphylococcus aureus bacteraemia.Association between vancomycin trough concentration and area under the concentration-time curve in neonates Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children.In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.Achievement of Vancomycin Therapeutic Goals in Critically Ill Patients: Early Individualization May Be Beneficial.Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Vancomycin-associated renal dysfunction: where are we now?Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients.24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury.Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study The Nephrotoxicity of Vancomycin Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.Clinical Decision Support Tools: The Evolution of a Revolution.The use and risks of antibiotics in critically ill patients.Therapeutic drug monitoring of anti-infective agents in critically ill patients.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Optimization of anti-infective dosing regimens during online haemodiafiltration Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus.Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis.Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?

P2860

Q26746932-C74063EE-A6A8-44AF-BBBF-C9B5970B9452 Q26770913-5F7AC3D8-0BF6-4AFA-A53F-8912A948EDFC Q28069334-C91C1780-6ABE-4286-AFCE-17B41ED5F6AA Q30490223-760E222C-FD30-413F-897C-E664655FA8DE Q33885191-40ECA65B-3A2A-4CA3-B8EE-828832983DEA Q33949459-195E0AFC-5205-4777-BCF7-8EB205149D61 Q34415830-1C89DA88-0018-4AD3-BE76-883E8942D929 Q34596435-8225AB65-BCA2-4875-A786-71F02C133100 Q35607636-9D5750D1-8BE3-478E-A353-0AEB14EE10CF Q35607704-876CDB5C-9C9C-4BE0-9043-7FF410D37E45 Q35752756-611FCA39-700F-436E-9B7F-7648C60D078D Q36083619-FBC5E645-7C21-44B2-BED7-941CF0FE7CBD Q36216479-7ADD8FBF-B005-42F6-BF15-196A91E1D37E Q36377410-1EF7048D-957B-4ADE-96BE-4D8783D95879 Q36439072-BE591B4E-F0FA-4B7E-8E77-5F28C7F889ED Q36747464-81CE2298-EFBB-4B4D-883B-7104B378D534 Q37287739-28ABB9A3-F476-474D-9A80-DC7E160CA5CB Q38249103-FC2C70AC-E206-4EDE-ABDB-2A9052D71B6E Q38258649-66ED0770-4E36-446A-A6A3-522CE0CE02F4 Q38417173-F40658C0-481C-4AFB-93E1-44D15CE78784 Q38545589-B8B49359-DC36-4FEC-A5E2-BC068E274EE7 Q38610672-55CA23EC-E03B-4852-AF76-C5CFE15204E3 Q38625062-22C74B18-BE94-4C13-BC55-CCDBE35B3626 Q38648530-FC4BCD48-C5E7-40FB-986D-B4160E2378FB Q38687487-3AF5CF8B-85BD-48C8-8A3C-0E2AF4133473 Q38690127-6E4968F1-A398-4CA4-8431-014A607D4809 Q38702792-A799B699-8510-48E4-A66B-A19A62D75A81 Q38767901-D8ED78FB-0140-4DE9-9988-1697277CDA9F Q38790740-2A918036-320B-4DB8-A880-CEE580EA92F1 Q38837353-625BFDB7-0E09-47F9-A714-4AFD9C93B01B Q38843412-F386AEAD-A823-4596-89D4-02B056B4277C Q38910495-BBE7DD8D-09AE-4D02-B6CA-612AD53E98B7 Q38938708-4112ECAE-DD9A-426B-8527-BEEF294BCC2D Q39044128-679E39F6-DAAD-4AAD-BC9E-4DAB2A2C6E92 Q39061989-82124CC8-D574-470D-8365-B494191A4974 Q39334338-B916E3FA-026B-41C5-950E-F48749E61498 Q39471413-2196DA11-FFE2-4488-A938-47309FBE3EA1 Q39623184-60B8ED82-D4BF-41EA-8468-93DE74E89B9A Q40526316-2FA56229-1B22-44DF-9A05-6FE1FA02B6FB Q40716347-EBCB8394-48EA-4EBD-84B7-0EBF09A172DB

P2860

Are vancomycin trough concentrations adequate for optimal dosing?

http://www.wikidata.org/entity/Q37544400

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Are vancomycin trough concentrations adequate for optimal dosing?

@en

Are vancomycin trough concentrations adequate for optimal dosing?

@nl

type

label

Are vancomycin trough concentrations adequate for optimal dosing?

@en

Are vancomycin trough concentrations adequate for optimal dosing?

@nl

prefLabel

Are vancomycin trough concentrations adequate for optimal dosing?

@en

Are vancomycin trough concentrations adequate for optimal dosing?

@nl

P1433

Q37544400-27B164FB-B9CD-4AB5-B7C3-86B4024A1865

P1476

Q37544400-A341BB18-750F-409F-A1BD-A10D4BF1D3EC

P2093

Q37544400-11AE4FD5-623F-47C2-A60C-FB10789CF1B5

Q37544400-6F2D2A61-771E-495D-B50E-A772D3A11E40

Q37544400-7001D494-5016-4489-96D0-6A1778A7E6FE

Q37544400-7F903C33-C347-4FBD-BFE0-24EB4DC31175

Q37544400-83E75644-CE54-4A41-8453-93A3F06CF899

Q37544400-BE732A3F-DB62-4DCE-BA36-DD9191EAAC3C

Q37544400-D0170619-5559-403F-B69B-E84AFF8CD021

P2860

Q37544400-0E4B90A8-76B1-490D-A750-E0486EDFA59B

Q37544400-1056775F-A05A-4841-AA1D-86CA1E3EF089

Q37544400-28909BF6-DCE9-4E5B-A6A9-8B2CCF492223

Q37544400-361BC6F8-9C4A-4882-8451-2AF1DFE25444

Q37544400-3BEBC75C-BD61-493F-812D-65E361ED3A8A

Q37544400-3E6E42EF-AF1C-41B6-9A6E-8DD1727B07B3

Q37544400-4DCCD61B-B766-45C3-852B-2BC8981D3702

Q37544400-586F7A7D-094A-4132-8B10-EA38623F9653

Q37544400-59F452B9-BC67-4B08-B438-87A1D2039063

Q37544400-6084ED05-B2FE-4461-91CD-20B11AD65129

P304

Q37544400-92EAE8A0-17CD-44CE-8ED0-3BB5C7B81A59

P31

Q37544400-F7B15AA4-C16A-4C40-A4EC-EA62D369260E

P356

Q37544400-6204F7CB-6BCA-4845-BABC-6F2149356115

P407

Q37544400-F4C5540F-E42C-4C6F-B6E2-EAEC169A89CE

P433

Q37544400-2C19C5BC-3C88-4265-84DA-05C4A987C6D6

P478

Q37544400-8ED77147-D079-4083-BB40-8D402C81EC20

P577

Q37544400-1064FF74-106A-4E98-8499-F7ED8D7D8BB6

P698

Q37544400-312CB51B-9BDA-4CF1-A20A-50DB28D868B9

P932

Q37544400-7C40793C-6CBB-4D47-89B3-6D92CD823390

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Are vancomycin trough concentrations adequate for optimal dosing?

@en

P2093

Brenda Jones

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

Gilmer Youn

http://www.w3.org/2001/XMLSchema#string

Keith A Rodvold

http://www.w3.org/2001/XMLSchema#string

Michael N Neely

http://www.w3.org/2001/XMLSchema#string

Roger W Jelliffe

http://www.w3.org/2001/XMLSchema#string

Thomas P Lodise

http://www.w3.org/2001/XMLSchema#string

P2860

Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Application of a Bayesian method to monitor and adjust vancomycin dosage regimens

Vancomycin pharmacokinetics in patients with various degrees of renal function.

Penetration of vancomycin into epithelial lining fluid in healthy volunteers.

Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization

Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R

Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

P304

309-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01653-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24165176

http://www.w3.org/2001/XMLSchema#string

P932

3910745

http://www.w3.org/2001/XMLSchema#string